AIMS: To estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-2/COVID-19 disease.   DESIGN: Living rapid review of observational and experimental studies with random-effects hierarchical Bayesian meta-analyses. Published articles and pre-prints were identified via MEDLINE and medRxiv.   SETTING: Community or hospital. No restrictions on location. PARTICIPANTS: Adults who received a SARS-CoV-2 test or a COVID-19 diagnosis. MEASUREMENTS: Outcomes were SARS-CoV-2 infection, hospitalisation, disease severity and mortality stratified by smoking status. Study quality was assessed (i.e. ‘good’, ‘fair’ and ‘poor’). FINDINGS: v11 (searches up to 2021-02-16) included 405 studies with 62 ‘good’ and ‘fair’ quality studies included in unadjusted meta-analyses. 121 studies (29.9%) reported current, former and never smoking status with the remainder using broader categories. Recorded smoking prevalence among people with COVID-19 was generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS-CoV-2 infection (RR = 0.71, 95% Credible Interval (CrI) = 0.61-0.82, τ = 0.34). Data for former smokers were inconclusive (RR = 1.03, 95% CrI = 0.95-1.11, τ = 0.17) but favoured there being no important association (4% probability of RR ≥1.1). Former compared with never smokers were at increased risk of hospitalisation (RR = 1.19, CrI = 1.1-1.29, τ = 0.13), greater disease severity (RR = 1.8, CrI = 1.27-2.55, τ = 0.46) and mortality (RR = 1.56, CrI = 1.23-2, τ = 0.43). Data for current smokers on hospitalisation, disease severity and mortality were inconclusive (RR = 1.1, 95% CrI = 0.99-1.21, τ = 0.15; RR 1.26, 95% CrI = 0.92-1.73, τ = 0.32; RR = 1.12, 95% CrI = 0.84-1.47, τ = 0.42, respectively) but favoured there being no important associations with hospitalisation and mortality (49% and 56% probability of RR ≥1.1, respectively) and a small but important association with disease severity (83% probability of RR ≥1.1). CONCLUSIONS: Compared with never smokers, current smokers appear to be at reduced risk of SARS-CoV-2 infection while former smokers appear to be at increased risk of hospitalisation, greater disease severity and mortality from COVID-19. However, it is uncertain whether these associations are causal. v7 of this living review article has been published in _Addiction_ [https://doi-org.libproxy.ucl.ac.uk/10.1111/add.15276]